Multi-Institution Evaluation of Sequential Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guerin Naïve Patients with Non-Muscle Invasive Bladder Cancer
Lewis J. Thomas(Washington University in St. Louis), Michael A. O’Donnell(University of Iowa Health Care), Supriya Nagaraju(The University of Texas MD Anderson Cancer Center), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Sarah L. Mott(University of Iowa Holden Comprehensive Cancer Center), Trafford Crump(University of Calgary), Ian M. McElree(Vanderbilt University Medical Center), Donald L. Lamm(The University of Texas System), Kenneth G. Nepple(University of Iowa), Mounica Y. Rao(University of Arizona), Nathan A. Brooks(Eli Lilly (United States)), Trinity J. Bivalacqua(Hospital of the University of Pennsylvania), Vignesh T. Packiam(Rutgers, The State University of New Jersey), Eric Hyndman, Max Kates(Duke Medical Center), Ryan L. Steinberg(University of Iowa), Andrew Vitale(University of Iowa), Marcus J. Daniels(Johns Hopkins University)
Cited by 1
Related Papers
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
|Nature Reviews Urology|2022|196
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116
1,1-Bis(3′-indolyl)-1-( <i>p</i> -chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth
|Molecular Cancer Therapeutics|2008|104